What is Pfizer's braftovi/mektovi — revenues:?

Pfizer (PFE) reported braftovi/mektovi — revenues: of $174.00M in Q1 2026.

How has Pfizer's braftovi/mektovi — revenues: changed year-over-year?

Pfizer's braftovi/mektovi — revenues: increased by 27.9% year-over-year, from $136.00M to $174.00M.

What is the long-term trend for Pfizer's braftovi/mektovi — revenues:?

Over 3 years (2022 to 2025), Pfizer's braftovi/mektovi — revenues: has grown at a 16.3% compound annual growth rate (CAGR), from $456.00M to $717.00M.

Products & Services · Revenues:

Braftovi/Mektovi — Revenues:

Pfizer Braftovi/Mektovi — Revenues: decreased by 11.7% to $174.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 27.9%, from $136.00M to $174.00M. Over 3 years (FY 2022 to FY 2025), Braftovi/Mektovi — Revenues: shows an upward trend with a 16.3% CAGR.

Analysis

StatementSegment

First reportedQ1 2022

Last reportedQ1 2026May 5, 2026

Rolls up toTotal Revenue

Metric ID: pfe_segment_braftovi_mektovi_revenues

Historical Data

17 periods

	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q1 '24	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$114.00M	$114.00M	$114.00M	$114.00M	$103.00M	$113.00M	$131.00M	$131.00M	$116.00M	$148.00M	$173.00M	$170.00M	$136.00M	$182.00M	$202.00M	$197.00M	$174.00M
QoQ Change	—	+0.0%	+0.0%	+0.0%	-9.6%	+9.7%	+15.9%	+0.0%	-11.5%	+27.6%	+16.9%	-1.7%	-20.0%	+33.8%	+11.0%	-2.5%	-11.7%
YoY Change	—	—	—	—	-9.6%	-0.9%	+14.9%	+14.9%	+12.6%	+31.0%	+32.1%	+29.8%	+17.2%	+23.0%	+16.8%	+15.9%	+27.9%

Range$103.00M – $202.00M

CAGR+11.2%

Avg YoY Growth+17.3%

Median YoY Growth+16.8%

Current Streak2 quarters decline

Frequently Asked Questions

What is Pfizer's braftovi/mektovi — revenues:?: Pfizer (PFE) reported braftovi/mektovi — revenues: of $174.00M in Q1 2026.
How has Pfizer's braftovi/mektovi — revenues: changed year-over-year?: Pfizer's braftovi/mektovi — revenues: increased by 27.9% year-over-year, from $136.00M to $174.00M.
What is the long-term trend for Pfizer's braftovi/mektovi — revenues:?: Over 3 years (2022 to 2025), Pfizer's braftovi/mektovi — revenues: has grown at a 16.3% compound annual growth rate (CAGR), from $456.00M to $717.00M.